Advanced Oxidation Protein Product and Monocyte Chemoattractant Protein-1 in Periodontal Disease

Kırıkkale University

Status: Completed

Conditions: Inflammation; Periodontal Disease

Study type: Observational

Funder types: Other

Identifiers

NCT02848378

2014/17

Details and patient eligibility

About

This study investigates the levels of advanced oxidation protein product and monocyte chemoattractant protein-1 in gingival crevicular fluid in periodontal disease and health. 25 participants with chronic periodontitis, 25 participants with gingivitis and 25 periodontally healthy subjects are included into this study. In each participant, four sites are identified for gingival crevicular fluid samples.

Full description

Oxidative stress is the disequilibrium between the formation of free radicals and antioxidant defense mechanisms via damaging cellular macromolecules (DNA, protein, lipid, etc..) which are susceptible to oxidative damage.

Advanced oxidation protein product is identified as a new marker of protein oxidation.

Monocyte chemoattractant protein-1 is a major chemoattractant for lymphocytes, monocytes and macrophages.

Enrollment: 75 patients

Sex: All

Ages: 18 to 66 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of chronic periodontitis and gingivitis

Exclusion criteria

• Systemic illnesses
• Any medications known to affect the periodontium
• Pregnancy and lactation

Trial design

75 participants in 3 patient groups

Chronic periodontitis group

Description:

Subjects who have moderate to severe alveolar bone loss and clinical attachment level (CAL) ≥5 mm and probing depth (PD) ≥6mm in multiple sites of all four quadrants of the mouth but with no evidence of rapid progression

Gingivitis group

Description:

Subjects who show gingival inflammation that is based on the presence of bleeding on probing (BOP) at \>50% of sites in the whole mouth, no clinical and radiographic signs of periodontitis

Periodontally healthy group

Description:

Subjects who have no sites with PD \>3mm and CAL \>0 mm, a BOP score of \<15% at the examination and no alveolar bone loss.